Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Gains from Investment Securities (2021 - 2025)

Historic Gains from Investment Securities for Krystal Biotech (KRYS) over the last 5 years, with Q4 2025 value amounting to -$7.9 million.

  • Krystal Biotech's Gains from Investment Securities fell 96213.28% to -$7.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $6.0 million, marking a year-over-year decrease of 191.14%. This contributed to the annual value of $6.0 million for FY2025, which is 191.14% down from last year.
  • Latest data reveals that Krystal Biotech reported Gains from Investment Securities of -$7.9 million as of Q4 2025, which was down 96213.28% from $18000.0 recorded in Q3 2025.
  • In the past 5 years, Krystal Biotech's Gains from Investment Securities ranged from a high of $12.1 million in Q2 2025 and a low of -$7.9 million during Q4 2025
  • In the last 5 years, Krystal Biotech's Gains from Investment Securities had a median value of $1.4 million in 2022 and averaged $1.4 million.
  • In the last 5 years, Krystal Biotech's Gains from Investment Securities surged by 82345.68% in 2023 and then tumbled by 96213.28% in 2025.
  • Krystal Biotech's Gains from Investment Securities (Quarter) stood at $336000.0 in 2021, then crashed by 51.79% to $162000.0 in 2022, then skyrocketed by 644.44% to $1.2 million in 2023, then dropped by 23.8% to $919000.0 in 2024, then plummeted by 962.13% to -$7.9 million in 2025.
  • Its Gains from Investment Securities stands at -$7.9 million for Q4 2025, versus $18000.0 for Q3 2025 and $12.1 million for Q2 2025.